Entries open for Oxford-Harrington Rare Disease Scholar Award

Deadline: 09-Mar-2026

The Oxford–Harrington Rare Disease Scholar Award supports early-stage academic discoveries with strong potential to become patient-ready therapies for rare diseases. The programme provides £100,000 or USD 100,000 in funding, hands-on therapeutics development support, and access to advanced research infrastructure to accelerate translation into clinical practice.

The Oxford–Harrington Rare Disease Scholar Award is a competitive translational research funding program designed to advance promising rare disease discoveries from academic laboratories toward clinical application.

Delivered through the Oxford–Harrington Collaboration (OHC), the award combines non-dilutive funding, expert-led development support, and access to cutting-edge therapeutic platforms to de-risk early-stage projects and move them closer to patients.

What Is the Oxford–Harrington Collaboration (OHC)?

The Oxford–Harrington Collaboration is a transatlantic initiative focused on accelerating innovative academic research into viable therapeutic programs for rare diseases.

OHC bridges the gap between discovery science and clinical development by providing:

• Early-stage funding

• Industry-experienced development teams

• Translational infrastructure and platforms

• Commercialisation and investment readiness support

Focus Areas and Research Scope

Priority Disease Areas

While the OHC has defined focus areas, applications are not limited to these categories.

Current priority areas include:

• Neurological disorders

• Developmental and metabolic disorders

• Rare cancers

The programme also welcomes applications targeting other rare, genetic diseases with significant unmet medical need.

Definition of Rare Disease

Applicants may use either:

• European definition of a rare disease, or

• United States definition of a rare disease

Ultra-rare diseases are also eligible for consideration.

Types of Projects and Proposals of Interest

The award supports projects at the discovery, validation, or early development stage, particularly those with a clear translational pathway.

Proposals of interest include:

• Novel, validated biological targets

• Any therapeutic modality, including:

  • Small molecules

  • Proteins and biologics

  • Oligonucleotides

  • Cell and gene therapies

• Research demonstrating:

  • Rigorous scientific validation

  • Creativity and innovation

  • Strong potential for clinical impact

Key Evaluation Considerations

Applications are assessed holistically, with particular emphasis on:

• Novel approaches to treating rare diseases

• Clear potential to evolve into a commercial therapeutic programme

• Strong intellectual property (IP) position or protection strategy

• Feasibility of advancing toward preclinical and clinical development

• Relevance to patients with high unmet medical needs

What the Award Provides

Funding Support

Successful applicants receive a guaranteed grant award, distributed over two years:

• £100,000 for UK-based awardees

• USD 100,000 for US- and Canada-based awardees

Development and Project Management Support

In addition to funding, awardees receive:

• One year of structured therapeutics development support

• Dedicated project management

• Milestone-based guidance to advance translational readiness

Projects may be renewed for a second year of development support based on progress and milestone achievement.

Access to Advanced Research Infrastructure

Awardees gain access to OHC-supported platforms and facilities, including:

• Oligonucleotide synthesis and screening

• Small molecule and protein development platforms

• Cell and gene therapy research capabilities

Scholars may also:

• Compete for additional acceleration funding

• Qualify for significant follow-on investment funding based on project needs

Expert-Led Translational Support Model

Each Scholar is supported by a personalised therapeutics development team, which may include:

• Former senior leaders from the pharmaceutical industry

• Translational science and drug development experts

• A dedicated project manager

This team works closely with the awardee to de-risk the project, strengthen development strategy, and prepare it for clinical translation.

Intellectual property rights remain with the awardee or their institution.

Who Is Eligible?

Applicant Eligibility Criteria

Applicants must meet all of the following requirements:

• Hold an MD or PhD (or equivalent)

• Be based in the UK, United States, or Canada

• Operate an independent research laboratory

• Hold a faculty position at an:

  • Accredited academic medical centre

  • University

  • Research institution

• Conduct the majority of their work at the host institution

Project Leadership Requirements

• Each project must have one Principal Investigator (PI)

• The PI is responsible for:

  • Scientific oversight

  • Financial management

• Collaborators, core facilities, and commercial Contract Research Organisations (CROs) may participate in project execution

Why This Award Matters

The Oxford–Harrington Rare Disease Scholar Award addresses a critical funding and development gap by:

• Accelerating high-risk, high-impact rare disease research

• Supporting academic scientists beyond discovery

• Enabling patient-focused therapeutic development

• Increasing the likelihood of clinical translation and commercial viability

The program is particularly valuable for projects that are too early for traditional venture funding but too advanced for basic research grants.

How to Apply

Application Timeline

• Applications open: 14 January 2026

• Application deadline: 9 March 2026

• Due diligence review for finalists: June–July 2026

• Award notification: October 2026

Application Process

1. Prepare a proposal describing the scientific rationale, innovation, and translational potential

2. Clearly define the rare disease indication and unmet need

3. Outline the development pathway and IP strategy

4. Submit the application through the designated submission system before the deadline

Late applications are not accepted, unless delays result from documented technical issues with the submission platform.

Common Mistakes to Avoid

• Submitting projects without validated targets

• Weak or undefined intellectual property strategy

• Proposals lacking a clear path to clinical development

• Applying without an independent lab or faculty appointment

• Missing the submission deadline

Frequently Asked Questions (FAQ)

1. What stage of research is eligible?

Projects at the discovery, validation, or early development stage are eligible, particularly those ready for translational acceleration.

2. Are ultra-rare diseases eligible?

Yes. Ultra-rare diseases are explicitly considered.

3. Can non-priority disease areas apply?

Yes. Applications targeting other rare, genetic diseases with high unmet need are welcome.

4. Does the award take equity or IP rights?

No. Intellectual property remains with the awardee or their institution.

5. Is the funding guaranteed for all awardees?

Yes. All selected Scholars receive the guaranteed grant amount for their region.

6. Can collaborators or CROs be involved?

Yes. Collaborators, core labs, and commercial CROs may support project execution, but one PI must lead the project.

7. Can the development support be extended?

Yes. Development support may be renewed for a second year based on milestone progress.

Conclusion

The Oxford–Harrington Rare Disease Scholar Award is a high-impact opportunity for academic researchers seeking to translate innovative rare disease discoveries into patient-ready therapies. By combining targeted funding, expert development guidance, and world-class infrastructure, the program significantly increases the likelihood that early-stage research can progress toward real-world clinical impact.

For more information, visit Oxford-Harrington Rare Disease Centre.